Advaxis Inc (ADXS)
1.285
+0.04
(+2.80%)
USD |
OTCM |
Mar 30, 16:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 6.217M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -86.65% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.2631 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 99.96% |
News
Headline
Wire
Time (ET)
Globe Newswire
03/03 08:00
Globe Newswire
02/10 07:00
Advaxis Updates on the Phase 1 Clinical Trial of ADXS-504 for the Treatment of Early Prostate Cancer
Globe Newswire
01/12 08:04
SA Breaking News
10/19 07:08
Globe Newswire
09/12 18:40
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/14/2022 | -- | Results | Q4 2021 | -- | -- | -- | |
| 09/10/2021 | -- | Results | Q3 2021 | -- | -- | -- | |
| 06/14/2021 | -- | Results | Q2 2021 | -- | -- | -- | |
| 03/16/2021 | -- | Results | Q1 2021 | -- | -- | -- | |
| 01/25/2021 | -- | Results | Q4 2020 | -- | -- | -- | |
| 09/10/2020 | -- | Results | Q3 2020 | -- | -- | -- | |
| 06/11/2020 | -- | Results | Q2 2020 | -- | -- | -- | |
| 06/11/2020 | 11:00 EST | Earnings Call | Q2 2020 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
| Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer. |
| URL | https://www.advaxis.com |
| Investor Relations URL | http://ir.advaxis.com/ |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | Feb. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
|
|
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0.00% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 30, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 16.51M |
| Net Income (TTM) | -14.36M |
| Total Assets (Quarterly) | 25.93M |
| Total Liabilities (Quarterly) | 2.303M |
| Shareholders Equity (Quarterly) | 23.63M |
| Cash from Operations (TTM) | -15.28M |
| Cash from Investing (TTM) | -0.166M |
| Cash from Financing (TTM) | -0.956M |
Ratings
Profile
| Advaxis Inc is a clinical-stage biotechnology company operating in the United States. It focuses on the discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate-Specific Antigen (PSA) associated with prostate cancer. |
| URL | https://www.advaxis.com |
| Investor Relations URL | http://ir.advaxis.com/ |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | N/A |
| Last Earnings Release | Feb. 14, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
|
|
|
Low:--
High:--
|
|
| Price Target Std Dev |
|
| Price Target Upside (Daily) | Upgrade |
| Price Target Num Estimates | Upgrade |
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ADXS Tweets |